ArticleRMD open2023
Characterisation of patients with axial psoriatic arthritis and patients with axial spondyloarthritis and concomitant psoriasis in the SCQM registry.
Article in RMD open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Characterising axial psoriatic arthritis in clinical practice: a retrospective analysis from the Rheumatic Diseases Portuguese Registry.Journal of rheumatic diseases · 2026Article
- Patients' Journey and Burden of Disease Among Patients with Psoriatic Arthritis in Greece: A Cross-Sectional Survey.Mediterranean journal of rheumatology · 2026Article
- Time and patient journey to axial spondyloarthritis diagnosis: a retrospective study in French primary care.Rheumatology (Oxford, England) · 2026Article
- Patients' Journey and Burden of Disease Among Patients with Axial Spondyloarthritis in Greece: A Cross-Sectional Online Survey.Mediterranean journal of rheumatology · 2026Article
- Sacroiliac joint involvement in psoriatic arthritis - MRI, radiographic and clinical findings in 581 European routine care patients.Arthritis research & therapy · 2025Article
- Similarities and differences: disentangling the intersection between axial psoriatic arthritis and axial spondyloarthritis.Therapeutic advances in musculoskeletal disease · 2025Review
- Factors Associated with Axial Spondyloarthritis Remission in a Cohort of Saudi Patients with Longstanding Disease: A Multicenter Prospective Cohort Study.Current rheumatology reviews · 2025Article
- Impact of disease manifestations on first biologic drug survival in axial spondyloarthritis: a real-life Canadian study.Rheumatology advances in practice · 2025Article
- Efficacy and retention rate of secukinumab in psoriatic arthritis across different clinical phenotypes: insights from the Italian GISEA Registry.Therapeutic advances in musculoskeletal disease · 2025Article
- Article
- Axial Disease in Psoriatic Arthritis: A Challenging Domain in Clinical Practice.Diagnostics (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWithin the spectrum of spondyloarthritides, axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) present with overlapping features. Axial involvement in PsA (axial PsA) is treated according to recommendations for axSpA, as specific studies in axial PsA are scarce. We compared characteristics of patients with axSpA (particularly of patients with axSpA and concomitant psoriasis (pso)) with those of patients with axial PsA.
methodsPatients with axSpA and PsA in the Swiss Clinical Quality Management (SCQM) registry were included if information on pso and axial involvement was available. Patients with AxSpA were stratified by axSpA with and without pso (axSpA±pso) and patients with PsA were stratified to axial PsA or strictly peripheral PsA.
resultsPrevious or current psoriasis was observed in 479/4489 patients with axSpA (10.7%). Of 2631 patients with PsA, 1153 (43.8%) presented with axial involvement (opinion of the treating rheumatologist). Compared with patients with axSpA+pso, patients with axial PsA were older at symptom onset and at inclusion in SCQM, were less frequently HLA-B27 positive, had back pain less frequently and a higher prevalence of dactylitis and peripheral arthritis. A positive family history of pso or PsA was more frequent in axial PsA, while a positive family history of axSpA was more frequent in patients with axSpA+pso. Disease activity, function and mobility were comparable in axSpA+pso versus axial PsA.
conclusionPatients with axial PsA differ from patients with axSpA+pso in important demographic and clinical characteristics, and genetically, but present with a comparable disease burden. Treatment studies specifically dedicated to axial PsA seem warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.